Kilitch Drugs (India) Share Price

    NSE
    448
    +5.95 (1.35%)
    KILITCH • 01 Jul, 2025 | 12:18 PM
    BUY

    1Y Annualised Return

    27.88%

    3Y Annualised Return

    39.42%

    5Y Annualised Return

    35.85%

    The current prices are delayed, login or Open Demat Account for live prices.

    Kilitch Drugs (India) Stock Performance

    1W Return6.99
    1Y Return33.53
    Today's Low440
    Prev. Close442.05
    Mkt Cap (Cr.)710.92
    1M Return1.56
    3Y Return193.29
    52-Week High499
    Open450.90
    PE Ratio23.09
    6M Return37.02
    Today's High450.9
    52-Week Low299.95
    Face Value10

    Kilitch Drugs (India) Company background

    Founded in: 1992
    Managing director: Mukund P Mehta
    Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables Ophthalmic, Effervescent tablets Granules, Tablets Capsules, OTC range covering varied Nutraceuticals Cosmetics and Medical devices.The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.

    As of 01 Jul, 2025, Kilitch Drugs (India) share price is ₹448. The stock opened at ₹450.9 and had closed at ₹442 the previous day. During today’s trading session, Kilitch Drugs (India) share price moved between ₹440.00 and ₹450.90, with an average price for the day of ₹445.45. Over the last 52 weeks, the stock has recorded a low of ₹299.95 and a high of ₹499.00. In terms of performance, Kilitch Drugs (India) share price has increased by 37.3% over the past six months and has increased by 27.88% over the last year.

    Read More
    Kilitch Drugs (India) SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹74,99,950 (+15.38%)

    Daily SIP of 25,000 would have become 74,99,950 in 1 year with a gain of 9,99,950 (+15.38%)

    View details of Market Depth

    Kilitch Drugs (India) Fundamental

    Market Cap (in crs)

    710.92

    Face Value

    10

    Turnover (in lacs)

    22.23

    Key Metrics

    Qtr Change %
    49.36% Gain from 52W Low
    23.6
    Dividend yield 1yr %
    0

    Kilitch Drugs (India) Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Kilitch Drugs (India) Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    61.23 Cr
    56.17 Cr
    47.47 Cr
    33.45 Cr
    44.82 Cr
    Kilitch Drugs (India) Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    209.48 Cr
    158.85 Cr
    142.52 Cr
    117.14 Cr
    71.19 Cr
    57.45 Cr
    Kilitch Drugs (India) Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    10.22 Cr
    5.61 Cr
    8.61 Cr
    0.11 Cr
    3.68 Cr
    Kilitch Drugs (India) Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    24.56 Cr
    13.58 Cr
    8.28 Cr
    6.21 Cr
    3.77 Cr
    0.84 Cr

    Kilitch Drugs (India) Result Highlights

    • Kilitch Drugs (India) Ltd reported a 21.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 2.6%.

    • Its expenses for the quarter were down by 19.4% QoQ and 3.4% YoY.

    • The net profit decreased 34.4% QoQ and increased 26.9% YoY.

    • The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 2.2 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Kilitch Drugs (India)

    Promoter
    69.2%
    Public
    30.8%
    Promoter
    69.2%
    Public
    30.8%
    Promoter
    69.2%
    Public
    30.8%
    Promoter
    69.2%
    Public
    30.8%
    Promoter
    69.2%
    Public
    30.8%
    Promoter
    69.2%
    Public
    30.8%

    Kilitch Drugs (India) Technical Analysis

    Moving Averages Analysis
    448
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    433.40
    10Day EMA
    435.00
    12Day EMA
    435.80
    20Day EMA
    436.60
    26Day EMA
    434.80
    50Day EMA
    419.70
    100Day EMA
    392.80
    200Day EMA
    368.00
    5Day SMA
    429.10
    10Day SMA
    435.10
    20Day SMA
    439.80
    30Day SMA
    446.30
    50Day SMA
    422.10
    100Day SMA
    375.30
    150Day SMA
    359.10
    200Day SMA
    353.50
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    14889 Rs
    14889 Rs
    Week Rs
    7206 Rs
    7206 Rs
    Month Rs
    14291 Rs
    14291 Rs
    441.82
    Pivot
    Resistance
    First Resistance
    448.63
    Second Resistance
    455.22
    Third Resistance
    462.03
    Support
    First Support
    435.23
    Second support
    428.42
    Third Support
    421.83
    Relative Strength Index
    54.07
    Money Flow Index
    53.35
    MACD
    1.08
    MACD Signal
    4.35
    Average True Range
    19.83
    Average Directional Index
    15.54
    Rate of Change (21)
    0.22
    Rate of Change (125)
    36.25

    Kilitch Drugs (India) Latest News

    29 JUN 2025 | Sunday

    Kilitch Drugs India Ltd - 524500 - Closure of Trading Window

    29 JUN 2025 | Sunday

    Kilitch Drugs India Ltd - 524500 - Board Meeting Intimation for Considering And Approval Of The Proposal For Fund Raising By Way Of Issue Of Equity Shares Through Right Issue And Any Other Businesses

    22 MAY 2025 | Thursday

    Kilitch Drugs India Ltd - 524500 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    View More

    Kilitch Drugs (India) Share Price FAQs

    Kilitch Drugs (India) share price is ₹448 in NSE and ₹454.15 in BSE as on 1/7/2025.

    Kilitch Drugs (India) share price in the past 1-year return was 33.53. The Kilitch Drugs (India) share hit a 1-year low of Rs. 299.95 and a 1-year high of Rs. 499.

    The market cap of Kilitch Drugs (India) is Rs. 710.92 Cr. as of 1/7/2025.

    The PE ratios of Kilitch Drugs (India) is 23.09 as of 1/7/2025.

    The PB ratios of Kilitch Drugs (India) is 2.84 as of 1/7/2025

    You can easily buy Kilitch Drugs (India) shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Kilitch Drugs (India) share price is ₹499 and ₹299.95 as of 1/7/2025.

    Please be aware that Kilitch Drugs (India) stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    819.05
    -1.30 (-0.16%)
    1,523.90
    +23.30 (+1.55%)
    2,011.10
    +9.60 (+0.48%)
    1,605.70
    +3.90 (+0.24%)
    3,439.30
    -22.70 (-0.66%)
    Top Gainers
    7,473.00
    +231.00 (+3.19%)
    431.80
    +10.30 (+2.44%)
    1,529.30
    +28.70 (+1.91%)
    330.95
    +4.20 (+1.29%)
    881.55
    +9.45 (+1.08%)
    Top Losers
    1,173.70
    -25.50 (-2.13%)
    2,420.60
    -44.70 (-1.81%)
    260.75
    -3.40 (-1.29%)
    698.65
    -8.20 (-1.16%)
    6,152.50
    -65.00 (-1.05%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -